BACKGROUND: Interstitial fibrosis and tubular atrophy (IF/TA) in renal transplants are the major morphological correlates of progressive graft deterioration. Early diagnosis of IF/TA is a pre-requisite for a timely therapeutic intervention in patients at risk. To evaluate events occurring before the overt onset of IF/TA, gene expression profiling of 3-month protocol biopsies from patients with IF/TA was performed in a patient group (n = 8) who developed mild IF/TA [chronic allograft nephropathy (CAN) grade I, by the Banff scoring system] in the subsequent 6-month protocol biopsy ('progressors'), and in 12 patients without IF/TA at 6 months ('non-progressors'). METHODS: RNA was extracted, labelled and hybridized to human specific genome wide DNA microarrays. Normalized data were subjected to gene-centric and pathway-centric statistical methods. RESULTS: Compared to the non-progressors, the 3-month biopsies of the progressor group showed overexpression of several genes that are important in the T- and B-cell activation and immune response. Genes involved in pro-fibrotic processes were identified in the biopsies of the progressors that preceded the observed IF/TA at 6 months. Furthermore, several genes with transporter and metabolic functions were underrepresented in the progressors in the 3-month biopsies. CONCLUSION: Gene expression profiling of early protocol biopsies identified changes in the transcriptome of grafts, which may be important for the development of IF/TA. Such early detection of transcriptome changes can facilitate the identification of patients at risk shifting the intervention time point well before the histological diagnosis of irreversible IF/TA.
BACKGROUND: Interstitial fibrosis and tubular atrophy (IF/TA) in renal transplants are the major morphological correlates of progressive graft deterioration. Early diagnosis of IF/TA is a pre-requisite for a timely therapeutic intervention in patients at risk. To evaluate events occurring before the overt onset of IF/TA, gene expression profiling of 3-month protocol biopsies from patients with IF/TA was performed in a patient group (n = 8) who developed mild IF/TA [chronic allograft nephropathy (CAN) grade I, by the Banff scoring system] in the subsequent 6-month protocol biopsy ('progressors'), and in 12 patients without IF/TA at 6 months ('non-progressors'). METHODS: RNA was extracted, labelled and hybridized to human specific genome wide DNA microarrays. Normalized data were subjected to gene-centric and pathway-centric statistical methods. RESULTS: Compared to the non-progressors, the 3-month biopsies of the progressor group showed overexpression of several genes that are important in the T- and B-cell activation and immune response. Genes involved in pro-fibrotic processes were identified in the biopsies of the progressors that preceded the observed IF/TA at 6 months. Furthermore, several genes with transporter and metabolic functions were underrepresented in the progressors in the 3-month biopsies. CONCLUSION: Gene expression profiling of early protocol biopsies identified changes in the transcriptome of grafts, which may be important for the development of IF/TA. Such early detection of transcriptome changes can facilitate the identification of patients at risk shifting the intervention time point well before the histological diagnosis of irreversible IF/TA.
Authors: Maarten Naesens; Purvesh Khatri; Li Li; Tara K Sigdel; Matthew J Vitalone; Rong Chen; Atul J Butte; Oscar Salvatierra; Minnie M Sarwal Journal: Kidney Int Date: 2011-08-31 Impact factor: 10.612
Authors: Walter D Park; Matthew D Griffin; Lynn D Cornell; Fernando G Cosio; Mark D Stegall Journal: J Am Soc Nephrol Date: 2010-09-02 Impact factor: 10.121
Authors: R N Smith; B A Adam; I A Rosales; M Matsunami; T Oura; A B Cosimi; T Kawai; M Mengel; R B Colvin Journal: Am J Transplant Date: 2018-02-02 Impact factor: 8.086
Authors: R N Smith; M Matsunami; B A Adam; I A Rosales; T Oura; A B Cosimi; T Kawai; M Mengel; R B Colvin Journal: Am J Transplant Date: 2018-02-17 Impact factor: 8.086
Authors: M J Scian; D G Maluf; K G David; K J Archer; J L Suh; A R Wolen; M U Mba; H D Massey; A L King; T Gehr; A Cotterell; M Posner; V Mas Journal: Am J Transplant Date: 2011-07-27 Impact factor: 8.086